Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Stock Performance

Accelerate Diagnostics stock opened at $1.12 on Monday. The business’s 50-day simple moving average is $1.37 and its two-hundred day simple moving average is $1.54. The company has a market cap of $28.04 million, a PE ratio of -0.39 and a beta of 0.59. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $2.09.

Insider Transactions at Accelerate Diagnostics

In related news, Director John Patience bought 200,000 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the purchase, the director now directly owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This represents a 44.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 43.60% of the company’s stock.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is currently owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.